Search results
Showing 16 to 18 of 18 results for haemolytic anaemia
Patients with rare blood disorders to receive new treatment option, says NICE
In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).
Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE
Improved deal signals NICE recommendation of sickle cell treatment voxelotor.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.